melanoma

[Bristol Myers Squibb] Bristol Myers Squibb announced that OpdualagTM was approved by the FDA for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

[Proceedings of the National Academy of Sciences of the United States of America] Investigators showed that intermittent treatment with the BRAFV600E inhibitor, LGX818/encorafenib, suppressed growth compared with continuous treatment in human melanoma cells engineered to express BRAFV600E, p61-BRAFV600E, or MEK2C125 oncogenes.

[Experimental Cell Research] Scientists reported the unexpected finding that cellular loss of mixed-lineage protein kinase 3 (MLK3) in melanoma cells promoted cell invasion.

[Cancer Immunology Research] Using an aggressive melanoma tumor model, the authors targeted PSGL-1 in tumor-bearing mice and found increased effector CD4+ and CD8+ T cell responses and decreased regulatory T cells in tumors.

[Science Advances] ECM proteins, collagen I, collagen III, and elastin, blocked natural killer (NK) cell cytotoxicity and promoted their chemokine/cytokine production. NK cell cytotoxicity against major histocompatibility complex class I (MHC-I)–deficient melanoma in the skin was markedly increased by blocking tumor collagen deposition.

[Iovance Biotherapeutics, Inc.] Iovance Biotherapeutics, Inc. announced that the US FDA has allowed an IND to proceed for its first genetically modified TIL therapy, IOV-4001, for the treatment of unresectable or metastatic melanoma and stage III or IV NSCLC.